This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic
kidney disease (CKD) compared to people with normal kidneys. In the first part of the study,
half of CKD participants will be randomly assigned to ticagrelor and aspirin, while the other
half will be assigned to clopidogrel and aspirin in a blinded fashion. The treatment duration
will be two weeks. After recruiting CKD participants the investigator will recruit controls
with normal kidney function that will receive only ticagrelor and aspirin for two weeks.